Sorrento Therapeutics' COVID-19 Antibody Works Against Omicron Variant

Sorrento Therapeutics Inc SRNE has released new data on STI-9167, an advanced stage antibody against COVID-19.

  • The antibody was discovered and developed in an ongoing collaboration between Sorrento and the Icahn School of Medicine at Mount Sinai.
  • STI-9167 was observed to bind with high affinity and provide highly potent neutralizing activity against the omicron variant. 
  • The Company says that STI-9167 is unique compared to tests of EUA-approved SARS-CoV-2 antibodies in that binding and neutralization properties are maintained against the emerging omicron and omicron (+R346K) variant. 
  • Additionally, STI-9167 administered at a low dose (5mg/kg) by either the intranasal or intravenous routes provided robust protection against the clinical signs of infection by the Omicron variant mouse model of COVID-19.
  • It prevented weight loss and reduced virus titers in the lungs to undetectable levels.
  • Price Action: SRNE shares are up 0.23% at $4.32 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!